fingolimod hydrochloride has been researched along with Parkinson Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Camarillo, C; Chin, B; Herrera, GV; Perez, RG; Sarosiek, I; Vidal-Martinez, G; Yang, B | 1 |
| Choudhury, SR; Karmakar, S; Sardoiwala, MN | 1 |
| Boguszewski, PM; Kosson, P; Motyl, J; Przykaza, Ł; Strosznajder, JB | 1 |
| Dominguez, SJ; Garza, NT; Gil-Tommee, C; Medina, D; Perez, RG; Segura-Ulate, I; Vargas-Medrano, J; Vidal-Martínez, G; Yang, B | 1 |
| Li, M; Liu, Q; Wood, K; Yang, L; Yang, X; Zhao, P; Zhu, X | 1 |
| Chabwine, JN; Démonet, JF; du Pasquier, RA; Hirt, L; Kuntzer, T; Michel, P; Rossetti, AR; Schluep, M; Vingerhoets, FG | 1 |
6 other study(ies) available for fingolimod hydrochloride and Parkinson Disease
| Article | Year |
|---|---|
A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models.
Topics: Adult; Aged; Aged, 80 and over; Animals; Constipation; Disease Models, Animal; Dysbiosis; Female; Fingolimod Hydrochloride; Gastrointestinal Microbiome; Gastrointestinal Motility; Humans; Immunosuppressive Agents; Male; Mice; Mice, Transgenic; Microbiota; Middle Aged; Multiple System Atrophy; Parkinson Disease; Pilot Projects; RNA, Ribosomal, 16S | 2020 |
Chitosan nanocarrier for FTY720 enhanced delivery retards Parkinson's disease via PP2A-EzH2 signaling in vitro and ex vivo.
Topics: alpha-Synuclein; Animals; Biological Availability; Cell Line, Tumor; Chitosan; Disease Models, Animal; Drug Carriers; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Fingolimod Hydrochloride; Humans; Mice; Mice, Inbred BALB C; Neurons; Neuroprotective Agents; Parkinson Disease; Phosphorylation; Protein Aggregates; Protein Phosphatase 2; Proteolysis; Signal Transduction; Sphingosine 1 Phosphate Receptor Modulators; Ubiquitination | 2021 |
Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson's disease by activation of sphingosine kinase 1 and Akt kinase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; bcl-Associated Death Protein; Brain; Fingolimod Hydrochloride; Male; Mice; MPTP Poisoning; Neuroprotection; Parkinson Disease; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Pramipexole; Proto-Oncogene Proteins c-akt; Rotarod Performance Test; Tyrosine 3-Monooxygenase | 2018 |
FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF.
Topics: Aging; alpha-Synuclein; Animals; Brain-Derived Neurotrophic Factor; Fingolimod Hydrochloride; Gastrointestinal Motility; Humans; Mice; Mice, Transgenic; Parkinson Disease; Protein Precursors | 2016 |
Neuroprotective effects of fingolimod in mouse models of Parkinson's disease.
Topics: Animals; Cell Line, Tumor; Fingolimod Hydrochloride; Gene Expression Regulation; Humans; Male; Mice; Neuroblastoma; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Receptors, Lysosphingolipid; Rotenone; Sphingosine-1-Phosphate Receptors | 2017 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brain Stimulation; Dopamine Agonists; Epilepsy; Fingolimod Hydrochloride; Genetic Therapy; Humans; Immunosuppressive Agents; Ischemic Attack, Transient; Multiple Sclerosis; Muscular Diseases; Neurology; Parkinson Disease; Phenylenediamines; Polyneuropathies; Propylene Glycols; Sphingosine; Stroke; Treatment Outcome; Valproic Acid | 2012 |